{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T17:19:50Z","timestamp":1776273590403,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T00:00:00Z","timestamp":1326758400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1007\/s00280-012-1822-1","type":"journal-article","created":{"date-parts":[[2012,1,16]],"date-time":"2012-01-16T15:05:55Z","timestamp":1326726355000},"page":"1197-1204","source":"Crossref","is-referenced-by-count":75,"title":["Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study)"],"prefix":"10.1007","volume":"69","author":[{"given":"Masato","family":"Ozaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Omuro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Itoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisatsugu","family":"Mouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Hanada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasutoshi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iruru","family":"Maetani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinobu","family":"Okabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaji","family":"Tani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susumu","family":"Hijioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryouhei","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Ohoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Suyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Egawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Sofuni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Ikari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshifusa","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,1,17]]},"reference":[{"key":"1822_CR1","unstructured":"Ministry of Health, Labour and Welfare (2010) The dynamic statistics of the population in 2010. Available from http:\/\/www.mhlw.go.jp\/toukei\/saikin\/hw\/jinkou\/geppo\/nengai08\/toukei6.html . Accessed 26 July 2011"},{"key":"1822_CR2","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","volume":"15","author":"HA Burris 3rd","year":"1997","unstructured":"Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403\u20132413","journal-title":"J Clin Oncol"},{"key":"1822_CR3","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","volume":"25","author":"MJ Moore","year":"2007","unstructured":"Moore MJ et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960\u20131966","journal-title":"J Clin Oncol"},{"key":"1822_CR4","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1200\/JCO.2009.24.2446","volume":"27","author":"D Cunningham","year":"2009","unstructured":"Cunningham D et al (2009) Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 27:5513\u20135518","journal-title":"J Clin Oncol"},{"key":"1822_CR5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1517\/13543780902729412","volume":"18","author":"MW Saif","year":"2009","unstructured":"Saif MW et al (2009) S-1: a promising new oral fluoropyrimidine derivative. Expert Opin Investig Drugs 18:335\u2013348","journal-title":"Expert Opin Investig Drugs"},{"key":"1822_CR6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/jjco\/hyn127","volume":"39","author":"T Shirasaka","year":"2009","unstructured":"Shirasaka T (2009) Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas. Jpn J Clin Oncol 39:2\u201315","journal-title":"Jpn J Clin Oncol"},{"key":"1822_CR7","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000086771","volume":"68","author":"H Ueno","year":"2005","unstructured":"Ueno H et al (2005) An early phase II study of S-1 in patients with metastatic pancreatic cancer. Oncology 68:171\u2013178","journal-title":"Oncology"},{"key":"1822_CR8","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00280-007-0514-8","volume":"61","author":"T Okusaka","year":"2008","unstructured":"Okusaka T et al (2008) A late phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother Pharmacol 61:615\u2013621","journal-title":"Cancer Chemother Pharmacol"},{"key":"1822_CR9","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1038\/sj.bjc.6603168","volume":"94","author":"K Nakamura","year":"2006","unstructured":"Nakamura K et al (2006) Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer 94:1575\u20131579","journal-title":"Br J Cancer"},{"key":"1822_CR10","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00280-008-0918-0","volume":"64","author":"GW Lee","year":"2009","unstructured":"Lee GW et al (2009) Phase II trial of S-1 in combination with gemcitabine for chemo-naive patients with locally advanced or metastatic pancreatic cancer. Cancer Chemother Pharmacol 64:707\u2013713","journal-title":"Cancer Chemother Pharmacol"},{"key":"1822_CR11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/jjco\/hyn126","volume":"39","author":"MK Kim","year":"2009","unstructured":"Kim MK et al (2009) S-1 and gemcitabine as an outpatient-based regimen in patients with advanced or metastatic pancreatic cancer. Jpn J Clin Oncol 39:49\u201353","journal-title":"Jpn J Clin Oncol"},{"key":"1822_CR12","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00280-009-1059-9","volume":"65","author":"DY Oh","year":"2010","unstructured":"Oh DY et al (2010) A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer. Cancer Chemother Pharmacol 65:527\u2013536","journal-title":"Cancer Chemother Pharmacol"},{"key":"1822_CR13","doi-asserted-by":"crossref","unstructured":"Ueno H et al (2011) Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer. Jpn J Clin Oncol","DOI":"10.1093\/jjco\/hyr090"},{"key":"1822_CR14","doi-asserted-by":"crossref","unstructured":"Ioka T et al (2011) Randomized phase III study of gemcitabine plus S-1 versus S-1 versus gemcitabine in unresectable advanced pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol 29(suppl; abstr 4007)","DOI":"10.1200\/jco.2011.29.15_suppl.4007"},{"key":"1822_CR15","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1200\/JCO.2002.11.149","volume":"20","author":"JD Berlin","year":"2002","unstructured":"Berlin JD et al (2002) Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20:3270\u20133275","journal-title":"J Clin Oncol"},{"key":"1822_CR16","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1200\/JCO.2009.24.2446","volume":"27","author":"D Cunningham","year":"2009","unstructured":"Cunningham D et al (2009) Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 27:5513\u20135518","journal-title":"J Clin Oncol"},{"key":"1822_CR17","doi-asserted-by":"crossref","unstructured":"Isayama H et al (2011) The final analysis of a multicenter randomized controlled trial of gemcitabine (G) alone versus gemcitabine and S-1 combination therapy (GS) in patients with unresectable advanced pancreatic cancer (PC): GEMSAP study. J Clin Oncol 29(suppl; abstr 4040)","DOI":"10.1200\/jco.2011.29.15_suppl.4040"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-012-1822-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-012-1822-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-012-1822-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,22]],"date-time":"2019-06-22T15:01:09Z","timestamp":1561215669000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-012-1822-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,17]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["1822"],"URL":"https:\/\/doi.org\/10.1007\/s00280-012-1822-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,17]]}}}